FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q90253350> ?p ?o ?g. }

• Q90253350 description "2020 թվականի մարտի 11-ին հրատարակված գիտական հոդված" @default.
• Q90253350 description "article scientifique publié en 2020" @default.
• Q90253350 description "artykuł naukowy opublikowany 11 marca 2020" @default.
• Q90253350 description "artículu científicu espublizáu en marzu de 2020" @default.
• Q90253350 description "im März 2020 veröffentlichter wissenschaftlicher Artikel" @default.
• Q90253350 description "scientific article published on 11 March 2020" @default.
• Q90253350 description "wetenschappelijk artikel" @default.
• Q90253350 description "наукова стаття, опублікована 11 березня 2020" @default.
• Q90253350 name "TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study" @default.
• Q90253350 name "TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study" @default.
• Q90253350 type Item @default.
• Q90253350 label "TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study" @default.
• Q90253350 label "TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study" @default.
• Q90253350 prefLabel "TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study" @default.
• Q90253350 prefLabel "TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study" @default.
• Q90253350 P1433 Q90253350-295B667C-9390-480F-9BD1-0BA4F7F5791F @default.
• Q90253350 P1476 Q90253350-1DDF3104-C816-4206-AAC9-E83E56A1C586 @default.
• Q90253350 P2093 Q90253350-2C73A35C-4D27-42B7-AFF8-605B7C32D185 @default.
• Q90253350 P2093 Q90253350-8869364B-646E-47C6-94E5-056D00B27E05 @default.
• Q90253350 P2093 Q90253350-8C589A70-4703-4855-95F6-B9B5C4E3064D @default.
• Q90253350 P2093 Q90253350-C52C84E0-7B05-4BE2-AB74-62BA167997CF @default.
• Q90253350 P2093 Q90253350-CAE7BAD5-9EC2-4801-8520-22622E4624E5 @default.
• Q90253350 P2093 Q90253350-F3A103E2-EEA9-40A2-8425-0C18158DFF3F @default.
• Q90253350 P2093 Q90253350-F4AB2CB5-5132-4CA5-A2D0-18A4A95FC6B9 @default.
• Q90253350 P2860 Q90253350-02A46453-4E1C-4A50-8FF3-6628ED8A1239 @default.
• Q90253350 P2860 Q90253350-05E8BF86-F797-4CBD-9B0C-AEC183963B3F @default.
• Q90253350 P2860 Q90253350-114CE398-73EF-4837-8591-D00CD2A67CB7 @default.
• Q90253350 P2860 Q90253350-1271BC19-1C39-4B66-BE52-959C076461B5 @default.
• Q90253350 P2860 Q90253350-23C3E6E2-6FC7-4BCF-B346-11B860E4E124 @default.
• Q90253350 P2860 Q90253350-27322492-0B22-42B7-A300-9A24DF55B295 @default.
• Q90253350 P2860 Q90253350-2D7D53E4-0B16-4C5C-B38C-9EB054D2131C @default.
• Q90253350 P2860 Q90253350-415FFDBD-27A0-4AB6-B974-5A2ABEF7DE7A @default.
• Q90253350 P2860 Q90253350-4551D70F-3CA2-40CE-B26E-FDEA8C2B4288 @default.
• Q90253350 P2860 Q90253350-4A55E315-9882-4F58-94AA-7848F000066A @default.
• Q90253350 P2860 Q90253350-59598F1A-0300-4EEE-8B3A-C873E4D4B1CE @default.
• Q90253350 P2860 Q90253350-5E23B30D-3C2D-4802-BA9A-9191B4B17715 @default.
• Q90253350 P2860 Q90253350-62018AE8-98FC-410F-B215-A5A952231D58 @default.
• Q90253350 P2860 Q90253350-70692E61-FE3D-4EAD-9E81-B7E7DFDB1E29 @default.
• Q90253350 P2860 Q90253350-812FAE8D-05D0-4B77-B4DB-65555169F77D @default.
• Q90253350 P2860 Q90253350-8B1C6702-CDE9-4A65-B93B-3FCB3CF78C8D @default.
• Q90253350 P2860 Q90253350-907F16A0-B0D0-41FF-92CD-F1B5633A6B4A @default.
• Q90253350 P2860 Q90253350-9D96D5BD-43A2-45EC-A8C8-5B3BCBBF3303 @default.
• Q90253350 P2860 Q90253350-A1ADBBF9-51EB-45F8-BB07-62A12AD931E7 @default.
• Q90253350 P2860 Q90253350-B62593FB-DF50-49F4-B318-4F699946D393 @default.
• Q90253350 P2860 Q90253350-BA54CE4C-B829-467E-9A49-C700EF1679E4 @default.
• Q90253350 P2860 Q90253350-BDDDC96C-0AAF-4321-AB6C-55C195F9CE83 @default.
• Q90253350 P2860 Q90253350-BFBE6E65-6FFD-444D-B531-794586900BED @default.
• Q90253350 P2860 Q90253350-CAE5D56D-A513-4B2F-8F48-F956952C5E2E @default.
• Q90253350 P2860 Q90253350-CC0AB4F2-4C73-4ABF-BEAB-BE1F0A91495F @default.
• Q90253350 P2860 Q90253350-E53E5753-3739-4F93-A0D3-23DF3811FA7A @default.
• Q90253350 P2860 Q90253350-E5751951-0467-4885-ADEB-63BCDF1514A2 @default.
• Q90253350 P2860 Q90253350-EDABAEC0-3198-4B82-B1E6-0F50CF222FA0 @default.
• Q90253350 P2860 Q90253350-EFD73B69-800E-4869-8829-5D48A66A77A5 @default.
• Q90253350 P2860 Q90253350-FA165B05-D46D-4A67-A34E-0C047C43D974 @default.
• Q90253350 P31 Q90253350-7C95E673-49E2-4DA5-B5A4-54351A29742A @default.
• Q90253350 P356 Q90253350-C3848667-866A-4F84-B704-B6A8DE535020 @default.
• Q90253350 P577 Q90253350-9680D957-A0E3-41D6-B8C9-32B438094BCA @default.
• Q90253350 P698 Q90253350-EC4AB874-4AFE-4E14-BA1F-77208AE41FA4 @default.
• Q90253350 P921 Q90253350-4C65D894-30DA-470C-B424-2E5BDA43FEC5 @default.
• Q90253350 P921 Q90253350-5FAFF271-2E30-456B-901C-11FDB7AA94F5 @default.
• Q90253350 P921 Q90253350-75EDDDEF-9AC0-4EAE-B5D3-C3838BA87F15 @default.
• Q90253350 P921 Q90253350-DD0760EC-2252-49D3-A35A-116ABA38E4F6 @default.
• Q90253350 P932 Q90253350-A52153CD-F3F8-4F37-B62D-10BD405A7C02 @default.
• Q90253350 P356 S12471-020-01407-Z @default.
• Q90253350 P698 32162204 @default.
• Q90253350 P1433 Q26842349 @default.
• Q90253350 P1476 "TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study" @default.
• Q90253350 P2093 "A A van de Bovenkamp" @default.
• Q90253350 P2093 "A C van Rossum" @default.
• Q90253350 P2093 "A J Bakermans" @default.
• Q90253350 P2093 "A J Nederveen" @default.
• Q90253350 P2093 "C P Allaart" @default.
• Q90253350 P2093 "M L Handoko" @default.
• Q90253350 P2093 "W E M Kok" @default.
• Q90253350 P2860 Q26766355 @default.
• Q90253350 P2860 Q26850196 @default.
• Q90253350 P2860 Q28073894 @default.
• Q90253350 P2860 Q28252937 @default.
• Q90253350 P2860 Q32172320 @default.
• Q90253350 P2860 Q34527664 @default.
• Q90253350 P2860 Q34819581 @default.
• Q90253350 P2860 Q35115055 @default.
• Q90253350 P2860 Q35166962 @default.
• Q90253350 P2860 Q37328507 @default.
• Q90253350 P2860 Q37699474 @default.
• Q90253350 P2860 Q38222648 @default.
• Q90253350 P2860 Q38382930 @default.
• Q90253350 P2860 Q38384591 @default.
• Q90253350 P2860 Q38652938 @default.
• Q90253350 P2860 Q39334553 @default.
• Q90253350 P2860 Q40256097 @default.
• Q90253350 P2860 Q44522162 @default.
• Q90253350 P2860 Q45238933 @default.
• Q90253350 P2860 Q45921765 @default.
• Q90253350 P2860 Q46970736 @default.
• Q90253350 P2860 Q47141564 @default.
• Q90253350 P2860 Q47344617 @default.
• Q90253350 P2860 Q47618347 @default.
• Q90253350 P2860 Q50865900 @default.
• Q90253350 P2860 Q70025015 @default.

• next